Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

SANOFI : Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/22/2013 | 01:09am EDT

PRESS RELEASE

Hexyon/Hexacima 6-in-1 Pediatric Vaccine Approved in Europe - Hexyon/Hexacima is the only fully liquid, ready-to-use, 6-in-1 pediatric vaccine - Lyon, France - April 22, 2013 - Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN

and NYSE: SNY), announced today that the European Commission approved Sanofi Pasteur's 6-in-
1 pediatric vaccine HexyonTM/Hexacima® (DTaP-IPV-Hib-HepB vaccine) for primary and booster vaccination of infants from six weeks of age.
HexyonTM/Hexacima® is the only fully liquid, ready-to-use, 6-in-1 vaccine to protect infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
The new vaccine will be commercialized under the brand name HexyonTM in Western European countries* by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima® in Eastern European countries by Sanofi Pasteur.

"Hexyon/Hexacima ready-to-use, 6-in-1 pediatric vaccine will raise the standard of care of vaccination for millions of children. It reduces the number of vaccination visits for infants and it is more convenient for parents to complete the recommended vaccination schedule and thus better protect their children against six major childhood diseases," said Olivier Charmeil, President and CEO of Sanofi Pasteur. "We will introduce Hexyon/Hexacima vaccine in countries that are looking for improved and effective solutions for public immunization programs."

Key benefits of HexyonTM/Hexacima® vaccine:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
01:33aSanofi Gets Exclusive Over-The-Counter Rights to Tamiflu in the US From Roche
DJ
01:01aSANOFI : signs strategic deal for exclusive US over-the-counter rights to Tamifl..
GL
07/19MYOKARDIA : Announces HCM Program Updates Accelerates Timing for Mavacamten Topl..
AQ
07/18MyoKardia Accelerates Timing for Mavacamten Topline Phase 3 Data
DJ
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15SANOFI : Press releases
PU
07/10SANOFI : FDA to Review Isatuximab for Relapsed/Refractory Multiple Myeloma
DJ
07/10SANOFI : Press releases
PU
07/10SANOFI : FDA to review isatuximab as a potential treatment for relapsed/refracto..
GL
More news
Financials (EUR)
Sales 2019 35 757 M
EBIT 2019 9 365 M
Net income 2019 4 912 M
Debt 2019 15 013 M
Yield 2019 4,16%
P/E ratio 2019 19,7x
P/E ratio 2020 16,6x
EV / Sales2019 3,06x
EV / Sales2020 2,86x
Capitalization 94 258 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 86,72  €
Last Close Price 75,41  €
Spread / Highest target 32,6%
Spread / Average Target 15,0%
Spread / Lowest Target 4,76%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-0.33%105 753
JOHNSON & JOHNSON-0.32%345 980
PFIZER-1.90%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273